Heron Therapeutics Inc. (HRTX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Heron Therapeutics Inc. (HRTX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.47

-0.07 (-4.55%)

At close: Jan 14, 2025, 3:59 PM

1.47

0.34%

After-hours Jan 14, 2025, 05:03 PM EST

undefined% (undefined)

Bid	1.47
Market Cap	222.82M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.16
PE Ratio (ttm)	-9.16
Forward PE	n/a
Analyst	Buy

Ask	1.55
Volume	1,198,692
Avg. Volume (20D)	3,196,039
Open	1.57
Previous Close	1.54
Day's Range	1.46 - 1.58
52-Week Range	1.04 - 3.93
Beta	undefined

About HRTX

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acut...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Aug 26, 1987

Employees 126

Stock Exchange NASDAQ

Ticker Symbol HRTX

Website https://www.herontx.com

Analyst Forecast

According to 3 analyst ratings, the average rating for HRTX stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 309.56% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Heron Therapeutics Inc. is scheduled to release its earnings on Mar 11, 2025, during market hours.
Analysts project revenue of $37.37M, reflecting a 9.16% YoY growth and earnings per share of -0.03, making a -57.14% decrease YoY.

Why Price Moved

1 month ago · Source

+38.98%

Heron Therapeutics shares are trading higher. Need... Unlock content with Pro Subscription

2 months ago · Source

-30.43%

Heron Therapeutics shares are trading lower after the company reported worse-than-expected Q3 sales results and narrowed its FY24 product revenue guidance.

News

1 month ago · seekingalpha.com

Relief For Heron Therapeutics After The Court Win On Cinvanti

Heron Therapeutics won a court case securing Cinvanti's patents until 2035, and removing a significant legal overhang on its largest revenue contributor. The court win allows the company to focus on g...

2 months ago · seekingalpha.com

Heron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call Transcript

Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Melissa Jarel - Executive Director Craig Collard - Chief Executive Officer Ir...

2 months ago · zacks.com

Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare wi...

2 months ago · zacks.com

Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates

Heron Therapeutics (HRTX) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago.

2 months ago · zacks.com

Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics

Evaluate the expected performance of Heron Therapeutics (HRTX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its...